Financial Survey: Daré Bioscience (NASDAQ:DARE) & Allakos (NASDAQ:ALLK)

Daré Bioscience (NASDAQ:DARE) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Volatility & Risk

Daré Bioscience has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Allakos has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Daré Bioscience and Allakos, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daré Bioscience	0	1	2	0	2.67
Allakos	0	4	1	0	2.20

Daré Bioscience presently has a consensus price target of $24.00, indicating a potential upside of 730.45%. Allakos has a consensus price target of $2.00, indicating a potential upside of 507.35%. Given Daré Bioscience’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Daré Bioscience is more favorable than Allakos.

Profitability

This table compares Daré Bioscience and Allakos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daré Bioscience	-191.65%	N/A	-18.98%
Allakos	N/A	-140.87%	-86.22%

Institutional and Insider Ownership

6.7% of Daré Bioscience shares are held by institutional investors. Comparatively, 84.6% of Allakos shares are held by institutional investors. 4.0% of Daré Bioscience shares are held by insiders. Comparatively, 16.1% of Allakos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Daré Bioscience and Allakos”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daré Bioscience	$9,784.00	2,614.11	-$30.16 million	($0.51)	-5.67
Allakos	N/A	N/A	-$185.70 million	($1.32)	-0.25

Daré Bioscience has higher revenue and earnings than Allakos. Daré Bioscience is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks.

Summary

Daré Bioscience beats Allakos on 9 of the 13 factors compared between the two stocks.

About Daré Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

About Allakos

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.